Tony Scullion

Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA.

Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA.

Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA.

Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA.

Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA.